LB Bohle – 10.06.2025
Nipro Vialex – 26th January 2025
PCI – 7th June 2024
Temax_Krautz

Current Edition

Nasal & Pulmonary Drug Development
Novo Nordisk 20 March 2024, 11:21
Carterra – 24th March 2025
Stoelzle – 15th May 2025

AbbVie submits Rinvoq for ankylosing spondylitis

AbbVie has filed for approval of Rinvoq (upadacitinib) in the US to treat adult patients with active ankylosing spondylitis.

Ankylosing spondylitis is a chronic, progressive, inflammatory musculoskeletal disease impacting more than five million people worldwide, with a range of symptoms posing significant physical, psychological and economic burden on affected individuals.

The application is supported by data from SELECT-AXIS 1, in which the JAK inhibitor demonstrated significant improvements in signs and symptoms in patients with active ankylosing spondylitis, with twice as many patients (52%) achieving an (ASAS) 40 response versus placebo (26%).

“Ankylosing spondylitis is a debilitating disease that can cause severe pain, restricted mobility and lasting structural damage. With limited treatment options, innovation is crucial to help more patients living with active ankylosing spondylitis reach their treatment goals,” said Michael Severino, vice chairman and president, AbbVie.

“Rinvoq has the potential to improve care by helping to provide disease control, addressing pain and improving function.”

A regulatory application was also submitted to the EMA for the treatment of adult patients with active ankylosing spondylitis earlier this year, the firm noted.

Scott Pharma – 25.03.2025
Bespak – 21.05.2025
FujiFilm Skyscraper: 26th November 2024
Woolcool 26 March 2024, 16:16
Biopharma group 6 March 2024, 09:40
EyeC 18 March 2024, 13:10
Nipro – 09.06.2025
L.B. Bohle – 08.04.2025
Drug Discovery 2025, ELRIG – 04.07.2025